Common genetic risk factors are associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Intermediate repeat expansions at the Ataxin-2 locus (ATXN2) are a risk factor for ALS and influence the phenotype. We assessed whether ATXN2 is a risk factor for FTD or modify clinical features in a data set of Italian patients. Three hundred sixty-eight unrelated FTD cases and 342 controls were enrolled. The frequency of intermediate CAG repeats in ATXN2 gene was not different comparing patients and controls. CAG repeats were interrupted by CAA in all patients carrying intermediate repeats. Interestingly, patients with an increased number of CAG repeats had an earlier onset of the disease than those without expansions (p = 0.011), and presented more frequently with parkinsonism (p = 0.010), and psychotic symptoms (p = 0.013) at disease onset. Our study does not support a major role of ATXN2 intermediate CAG expansions in predisposing to FTD but suggests that ATXN2 may act as a phenotype modifier.

ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia

Rubino E;Mancini C;Boschi S;Ferrone M;Zucca M;Vacca A;Gai A;Giordana MT;Brusco A;Rainero I.
2019

Abstract

Common genetic risk factors are associated with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Intermediate repeat expansions at the Ataxin-2 locus (ATXN2) are a risk factor for ALS and influence the phenotype. We assessed whether ATXN2 is a risk factor for FTD or modify clinical features in a data set of Italian patients. Three hundred sixty-eight unrelated FTD cases and 342 controls were enrolled. The frequency of intermediate CAG repeats in ATXN2 gene was not different comparing patients and controls. CAG repeats were interrupted by CAA in all patients carrying intermediate repeats. Interestingly, patients with an increased number of CAG repeats had an earlier onset of the disease than those without expansions (p = 0.011), and presented more frequently with parkinsonism (p = 0.010), and psychotic symptoms (p = 0.013) at disease onset. Our study does not support a major role of ATXN2 intermediate CAG expansions in predisposing to FTD but suggests that ATXN2 may act as a phenotype modifier.
73
231
7
9
www.elsevier.com/locate/neuaging
ATXN2; Frontotemporal lobar degeneration; Intermediate expansions; polyQ repeats; SCA2; Neuroscience (all); Aging; Neurology (clinical); Developmental Biology; Geriatrics and Gerontology
Rubino E, Mancini C, Boschi S, Ferrero P, Ferrone M, Bianca S, Zucca M, Orsi L, Pinessi L4 Govone F, Vacca A, Gai A, Giordana MT, Brusco A, Rainero I.
File in questo prodotto:
File Dimensione Formato  
Post_print_ATXN2.docx

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 8.43 MB
Formato Microsoft Word XML
8.43 MB Microsoft Word XML   Visualizza/Apri   Richiedi una copia
127.SCA2_Rubino_NeurAging_2019.pdf

Accesso riservato

Descrizione: File principale
Tipo di file: PDF EDITORIALE
Dimensione 326.45 kB
Formato Adobe PDF
326.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Post_print_ATXN2.pdf

Accesso aperto con embargo fino al 22/09/2019

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 317.39 kB
Formato Adobe PDF
317.39 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1678968
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact